CABA
Cabaletta Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.55
−1.16%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.33
- Revenue estimate
- $1.7M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.34
- EPS estimate
- -$0.37
- Revenue actual
- —
- Revenue estimate
- $1.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +5.5%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $9.50
- PT range
- $3.00 – $16
- Analysts
- 2
1 Buy1 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.37 | -$0.34 | Beat 8.82% | — |
| May 14, 2026 | -$0.41 | -$0.39 | Beat 4.88% | — |
| Mar 23, 2026 | -$0.45 | -$0.40 | Beat 11.11% | — |
| Aug 7, 2025 | -$0.71 | -$0.73 | Miss -2.82% | — |
| May 15, 2025 | -$0.67 | -$0.71 | Miss -5.97% | — |
| Mar 31, 2025 | -$0.65 | -$0.65 | In line | $1.6M |
| Nov 14, 2024 | -$0.59 | -$0.62 | Miss -5.08% | — |
| Aug 8, 2024 | -$0.55 | -$0.56 | Miss -1.82% | — |
| May 15, 2024 | -$0.48 | -$0.51 | Miss -6.25% | — |
| Mar 21, 2024 | -$0.39 | -$0.46 | Miss -17.95% | $4.0M |
| Nov 9, 2023 | -$0.39 | -$0.37 | Beat 5.13% | — |
| Aug 10, 2023 | -$0.47 | -$0.37 | Beat 21.28% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026